Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868702 | 1.00 | PDCD1LG2 (0.52) | PDCD1LG2CD274DRD4CYP3A4SIGMAR1 | |
| SCHEMBL6195713 | 0.92 | DRD4 (0.59) | DRD4SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL13490514 | 0.91 | CYP3A4 (0.58) | DRD4CYP3A4SIGMAR1CYP2C9CYP2D6 | |
| SCHEMBL1740324 | 0.84 | CYP2D6 (0.52) | DRD4CYP3A4SIGMAR1CYP2C9CYP2D6 | |
| SCHEMBL6350082 | 0.84 | PDCD1LG2 (0.53) | PDCD1LG2CD274DRD4CYP3A4SIGMAR1 | |
| SCHEMBL3845634 | 0.81 | DRD4 (0.50) | PDCD1LG2CD274DRD4DRD2DRD3 | |
| SCHEMBL21274017 | 0.81 | DRD4 (0.50) | PDCD1LG2CD274DRD4USP30DRD2 | |
| SCHEMBL19117549 | 0.81 | DRD4 (0.50) | PDCD1LG2CD274DRD4DRD2DRD3 | |
| SCHEMBL2636322 | 0.81 | BCHE (0.53) | DRD4USP30DRD2DRD3ACHE | |
| SCHEMBL25171592 | 0.80 | CNR2 (0.53) | DRD4CYP3A4CYP2C9CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-01-08 | — | — | US | disclosed |
| EP-2766353-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053725-A1 | 2-OXO-PIPERIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2013-04-18 | — | — | WO | disclosed |
| US-5622966-A | BACTERICIDES TREATING INFECTIONS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5446044-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5384407-A | Pyrrolidine compounds | WARNER-LAMBERT COMPANY (US) | 1995-01-24 | — | — | US | disclosed |
| US-5342844-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1993016077-A1 | 7-SUBSTITUTED QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5221676-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | PDCD1LG2 3188/4885CD274 3184/4885DRD4 3096/4885 |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | PDCD1LG2 2852/4885CD274 3217/4885DRD4 3440/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | PDCD1LG2 2852/4885CD274 3217/4885DRD4 3440/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | PDCD1LG2 3038/4885CD274 3390/4885DRD4 4231/4885 |
| US-20150011526-A1 | 2-Oxo-Piperidinyl Derivatives | CYP3A4, CYP2C19, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDCD1LG2 3412/4885CD274 3860/4885DRD4 245/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | PDCD1LG2 2940/4885CD274 3128/4885DRD4 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.